Global Neurodegenerative Diseases Therapeutics Market Research Report 2024

Report ID: 1754233 | Published Date: Jan 2025 | No. of Page: 91 | Base Year: 2024 | Rating: 5 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
        1.2.2 Multiple Sclerosis Therapeutics
        1.2.3 Alzheimer's Disease Therapeutics
        1.2.4 Parkinson's Disease Therapeutics
        1.2.5 Parkinson's Disease Therapeutics
        1.2.6 Others
    1.3 Market by Application
        1.3.1 Global Neurodegenerative Diseases Therapeutics Market Share by Application: 2017 VS 2021 VS 2028
        1.3.2 Child
        1.3.3 Aldult
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Neurodegenerative Diseases Therapeutics Market Perspective (2017-2028)
    2.2 Neurodegenerative Diseases Therapeutics Growth Trends by Region
        2.2.1 Neurodegenerative Diseases Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Neurodegenerative Diseases Therapeutics Historic Market Size by Region (2017-2022)
        2.2.3 Neurodegenerative Diseases Therapeutics Forecasted Market Size by Region (2023-2028)
    2.3 Neurodegenerative Diseases Therapeutics Market Dynamics
        2.3.1 Neurodegenerative Diseases Therapeutics Industry Trends
        2.3.2 Neurodegenerative Diseases Therapeutics Market Drivers
        2.3.3 Neurodegenerative Diseases Therapeutics Market Challenges
        2.3.4 Neurodegenerative Diseases Therapeutics Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Neurodegenerative Diseases Therapeutics Players by Revenue
        3.1.1 Global Top Neurodegenerative Diseases Therapeutics Players by Revenue (2017-2022)
        3.1.2 Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Players (2017-2022)
    3.2 Global Neurodegenerative Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Neurodegenerative Diseases Therapeutics Revenue
    3.4 Global Neurodegenerative Diseases Therapeutics Market Concentration Ratio
        3.4.1 Global Neurodegenerative Diseases Therapeutics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Diseases Therapeutics Revenue in 2021
    3.5 Neurodegenerative Diseases Therapeutics Key Players Head office and Area Served
    3.6 Key Players Neurodegenerative Diseases Therapeutics Product Solution and Service
    3.7 Date of Enter into Neurodegenerative Diseases Therapeutics Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Diseases Therapeutics Breakdown Data by Type
    4.1 Global Neurodegenerative Diseases Therapeutics Historic Market Size by Type (2017-2022)
    4.2 Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Type (2023-2028)
5 Neurodegenerative Diseases Therapeutics Breakdown Data by Application
    5.1 Global Neurodegenerative Diseases Therapeutics Historic Market Size by Application (2017-2022)
    5.2 Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Neurodegenerative Diseases Therapeutics Market Size (2017-2028)
    6.2 North America Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022)
    6.3 North America Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028)
    6.4 United States
    6.5 Canada
7 Europe
    7.1 Europe Neurodegenerative Diseases Therapeutics Market Size (2017-2028)
    7.2 Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022)
    7.3 Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028)
    7.4 Germany
    7.5 France
    7.6 U.K.
    7.7 Italy
    7.8 Russia
    7.9 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size (2017-2028)
    8.2 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022)
    8.3 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028)
    8.4 China
    8.5 Japan
    8.6 South Korea
    8.7 Southeast Asia
    8.8 India
    8.9 Australia
9 Latin America
    9.1 Latin America Neurodegenerative Diseases Therapeutics Market Size (2017-2028)
    9.2 Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022)
    9.3 Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028)
    9.4 Mexico
    9.5 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size (2017-2028)
    10.2 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022)
    10.3 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028)
    10.4 Turkey
    10.5 Saudi Arabia
    10.6 UAE
11 Key Players Profiles
    11.1 AB Science SA
        11.1.1 AB Science SA Company Detail
        11.1.2 AB Science SA Business Overview
        11.1.3 AB Science SA Neurodegenerative Diseases Therapeutics Introduction
        11.1.4 AB Science SA Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
        11.1.5 AB Science SA Recent Development
    11.2 AbbVie Inc.
        11.2.1 AbbVie Inc. Company Detail
        11.2.2 AbbVie Inc. Business Overview
        11.2.3 AbbVie Inc. Neurodegenerative Diseases Therapeutics Introduction
        11.2.4 AbbVie Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
        11.2.5 AbbVie Inc. Recent Development
    11.3 Acadia Pharmaceuticals Inc.
        11.3.1 Acadia Pharmaceuticals Inc. Company Detail
        11.3.2 Acadia Pharmaceuticals Inc. Business Overview
        11.3.3 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Introduction
        11.3.4 Acadia Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
        11.3.5 Acadia Pharmaceuticals Inc. Recent Development
    11.4 Biogen Inc.
        11.4.1 Biogen Inc. Company Detail
        11.4.2 Biogen Inc. Business Overview
        11.4.3 Biogen Inc. Neurodegenerative Diseases Therapeutics Introduction
        11.4.4 Biogen Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
        11.4.5 Biogen Inc. Recent Development
    11.5 F. Hoffmann La Roche Ltd.
        11.5.1 F. Hoffmann La Roche Ltd. Company Detail
        11.5.2 F. Hoffmann La Roche Ltd. Business Overview
        11.5.3 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Introduction
        11.5.4 F. Hoffmann La Roche Ltd. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
        11.5.5 F. Hoffmann La Roche Ltd. Recent Development
    11.6 H Lundbeck AS
        11.6.1 H Lundbeck AS Company Detail
        11.6.2 H Lundbeck AS Business Overview
        11.6.3 H Lundbeck AS Neurodegenerative Diseases Therapeutics Introduction
        11.6.4 H Lundbeck AS Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
        11.6.5 H Lundbeck AS Recent Development
    11.7 Mitsubishi Chemical Holdings Corp.
        11.7.1 Mitsubishi Chemical Holdings Corp. Company Detail
        11.7.2 Mitsubishi Chemical Holdings Corp. Business Overview
        11.7.3 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Introduction
        11.7.4 Mitsubishi Chemical Holdings Corp. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
        11.7.5 Mitsubishi Chemical Holdings Corp. Recent Development
    11.8 Novartis AG
        11.8.1 Novartis AG Company Detail
        11.8.2 Novartis AG Business Overview
        11.8.3 Novartis AG Neurodegenerative Diseases Therapeutics Introduction
        11.8.4 Novartis AG Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
        11.8.5 Novartis AG Recent Development
    11.9 Sanofi
        11.9.1 Sanofi Company Detail
        11.9.2 Sanofi Business Overview
        11.9.3 Sanofi Neurodegenerative Diseases Therapeutics Introduction
        11.9.4 Sanofi Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
        11.9.5 Sanofi Recent Development
    11.10 Teva Pharmaceutical Industries Ltd
        11.10.1 Teva Pharmaceutical Industries Ltd Company Detail
        11.10.2 Teva Pharmaceutical Industries Ltd Business Overview
        11.10.3 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Introduction
        11.10.4 Teva Pharmaceutical Industries Ltd Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
        11.10.5 Teva Pharmaceutical Industries Ltd Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables
    Table 1. Global Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Key Players of Multiple Sclerosis Therapeutics
    Table 3. Key Players of Alzheimer's Disease Therapeutics
    Table 4. Key Players of Parkinson's Disease Therapeutics
    Table 5. Key Players of Parkinson's Disease Therapeutics
    Table 6. Key Players of Others
    Table 7. Global Neurodegenerative Diseases Therapeutics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 8. Global Neurodegenerative Diseases Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 9. Global Neurodegenerative Diseases Therapeutics Market Size by Region (2017-2022) & (US$ Million)
    Table 10. Global Neurodegenerative Diseases Therapeutics Market Share by Region (2017-2022)
    Table 11. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 12. Global Neurodegenerative Diseases Therapeutics Market Share by Region (2023-2028)
    Table 13. Neurodegenerative Diseases Therapeutics Market Trends
    Table 14. Neurodegenerative Diseases Therapeutics Market Drivers
    Table 15. Neurodegenerative Diseases Therapeutics Market Challenges
    Table 16. Neurodegenerative Diseases Therapeutics Market Restraints
    Table 17. Global Neurodegenerative Diseases Therapeutics Revenue by Players (2017-2022) & (US$ Million)
    Table 18. Global Neurodegenerative Diseases Therapeutics Market Share by Players (2017-2022)
    Table 19. Global Top Neurodegenerative Diseases Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Therapeutics as of 2021)
    Table 20. Ranking of Global Top Neurodegenerative Diseases Therapeutics Companies by Revenue (US$ Million) in 2021
    Table 21. Global 5 Largest Players Market Share by Neurodegenerative Diseases Therapeutics Revenue (CR5 and HHI) & (2017-2022)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Neurodegenerative Diseases Therapeutics Product Solution and Service
    Table 24. Date of Enter into Neurodegenerative Diseases Therapeutics Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 27. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Type (2017-2022)
    Table 28. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 29. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Type (2023-2028)
    Table 30. Global Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 31. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Application (2017-2022)
    Table 32. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 33. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Application (2023-2028)
    Table 34. North America Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 35. North America Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 36. Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 37. Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 38. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2017-2022) & (US$ Million)
    Table 39. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2023-2028) & (US$ Million)
    Table 40. Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 41. Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 42. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 43. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 44. AB Science SA Company Detail
    Table 45. AB Science SA Business Overview
    Table 46. AB Science SA Neurodegenerative Diseases Therapeutics Product
    Table 47. AB Science SA Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
    Table 48. AB Science SA Recent Development
    Table 49. AbbVie Inc. Company Detail
    Table 50. AbbVie Inc. Business Overview
    Table 51. AbbVie Inc. Neurodegenerative Diseases Therapeutics Product
    Table 52. AbbVie Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
    Table 53. AbbVie Inc. Recent Development
    Table 54. Acadia Pharmaceuticals Inc. Company Detail
    Table 55. Acadia Pharmaceuticals Inc. Business Overview
    Table 56. Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Product
    Table 57. Acadia Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
    Table 58. Acadia Pharmaceuticals Inc. Recent Development
    Table 59. Biogen Inc. Company Detail
    Table 60. Biogen Inc. Business Overview
    Table 61. Biogen Inc. Neurodegenerative Diseases Therapeutics Product
    Table 62. Biogen Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
    Table 63. Biogen Inc. Recent Development
    Table 64. F. Hoffmann La Roche Ltd. Company Detail
    Table 65. F. Hoffmann La Roche Ltd. Business Overview
    Table 66. F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Product
    Table 67. F. Hoffmann La Roche Ltd. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
    Table 68. F. Hoffmann La Roche Ltd. Recent Development
    Table 69. H Lundbeck AS Company Detail
    Table 70. H Lundbeck AS Business Overview
    Table 71. H Lundbeck AS Neurodegenerative Diseases Therapeutics Product
    Table 72. H Lundbeck AS Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
    Table 73. H Lundbeck AS Recent Development
    Table 74. Mitsubishi Chemical Holdings Corp. Company Detail
    Table 75. Mitsubishi Chemical Holdings Corp. Business Overview
    Table 76. Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Product
    Table 77. Mitsubishi Chemical Holdings Corp. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
    Table 78. Mitsubishi Chemical Holdings Corp. Recent Development
    Table 79. Novartis AG Company Detail
    Table 80. Novartis AG Business Overview
    Table 81. Novartis AG Neurodegenerative Diseases Therapeutics Product
    Table 82. Novartis AG Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
    Table 83. Novartis AG Recent Development
    Table 84. Sanofi Company Detail
    Table 85. Sanofi Business Overview
    Table 86. Sanofi Neurodegenerative Diseases Therapeutics Product
    Table 87. Sanofi Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
    Table 88. Sanofi Recent Development
    Table 89. Teva Pharmaceutical Industries Ltd Company Detail
    Table 90. Teva Pharmaceutical Industries Ltd Business Overview
    Table 91. Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Product
    Table 92. Teva Pharmaceutical Industries Ltd Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
    Table 93. Teva Pharmaceutical Industries Ltd Recent Development
    Table 94. Research Programs/Design for This Report
    Table 95. Key Data Information from Secondary Sources
    Table 96. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Neurodegenerative Diseases Therapeutics Market Share by Type: 2021 VS 2028
    Figure 2. Multiple Sclerosis Therapeutics Features
    Figure 3. Alzheimer's Disease Therapeutics Features
    Figure 4. Parkinson's Disease Therapeutics Features
    Figure 5. Parkinson's Disease Therapeutics Features
    Figure 6. Others Features
    Figure 7. Global Neurodegenerative Diseases Therapeutics Market Share by Application in 2021 & 2028
    Figure 8. Child Case Studies
    Figure 9. Aldult Case Studies
    Figure 10. Neurodegenerative Diseases Therapeutics Report Years Considered
    Figure 11. Global Neurodegenerative Diseases Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 12. Global Neurodegenerative Diseases Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 13. Global Neurodegenerative Diseases Therapeutics Market Share by Region: 2021 VS 2028
    Figure 14. Global Neurodegenerative Diseases Therapeutics Market Share by Players in 2021
    Figure 15. Global Top Neurodegenerative Diseases Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Therapeutics as of 2021)
    Figure 16. The Top 10 and 5 Players Market Share by Neurodegenerative Diseases Therapeutics Revenue in 2021
    Figure 17. North America Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 18. North America Neurodegenerative Diseases Therapeutics Market Share by Country (2017-2028)
    Figure 19. United States Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 20. Canada Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 21. Europe Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. Europe Neurodegenerative Diseases Therapeutics Market Share by Country (2017-2028)
    Figure 23. Germany Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. France Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. U.K. Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. Italy Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Russia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Nordic Countries Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Share by Region (2017-2028)
    Figure 31. China Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Japan Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. South Korea Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Southeast Asia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. India Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Australia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Latin America Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Latin America Neurodegenerative Diseases Therapeutics Market Share by Country (2017-2028)
    Figure 39. Mexico Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Brazil Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Share by Country (2017-2028)
    Figure 43. Turkey Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. Saudi Arabia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 45. AB Science SA Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
    Figure 46. AbbVie Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
    Figure 47. Acadia Pharmaceuticals Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
    Figure 48. Biogen Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
    Figure 49. F. Hoffmann La Roche Ltd. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
    Figure 50. H Lundbeck AS Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
    Figure 51. Mitsubishi Chemical Holdings Corp. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
    Figure 52. Novartis AG Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
    Figure 53. Sanofi Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
    Figure 54. Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
    Figure 55. Bottom-up and Top-down Approaches for This Report
    Figure 56. Data Triangulation
    Figure 57. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
AB Science SA
AbbVie Inc.
Acadia Pharmaceuticals Inc.
Biogen Inc.
F. Hoffmann La Roche Ltd.
H Lundbeck AS
Mitsubishi Chemical Holdings Corp.
Novartis AG
Sanofi
Teva Pharmaceutical Industries Ltd
Frequently Asked Questions
Neurodegenerative Diseases Therapeutics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Neurodegenerative Diseases Therapeutics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Neurodegenerative Diseases Therapeutics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Electricity Trading

Electricity Trading market is segmented by players, region (country), by Type and by Application. ... Read More